You just read:

First Phase 3 Trial of Daratumumab in Combination with Standard Therapy in Relapsed/Refractory Multiple Myeloma Meets Primary Endpoint in Planned Interim Analysis

News provided by

Janssen Research & Development, LLC

Mar 30, 2016, 12:22 ET